ALDEYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 USD | -1.19% |
|
+5.85% | +18.52% |
| 05-02 | Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-25 | Transcript : Aldeyra Therapeutics, Inc. - Special Call |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 162.4 | 266.3 | 232.4 | 407.6 | 206.5 | 247.2 | - | - |
| Enterprise Value (EV) 1 | 162.4 | 266.3 | 18.08 | 407.6 | 206.5 | 247.2 | 247.2 | 247.2 |
| P/E ratio | -2.59 x | -6.18 x | -3.74 x | -6.57 x | -5.48 x | 80 x | -9.77 x | -15.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 7.45 x | 9.98 x | 4.33 x |
| EV / Revenue | - | - | - | - | - | 7.45 x | 9.98 x | 4.33 x |
| EV / EBITDA | - | - | -4.15 x | -6.53 x | - | -6.44 x | -5.84 x | -8.68 x |
| EV / FCF | - | -7.1 x | -4.13 x | -8.04 x | -4.93 x | -7.1 x | -4.19 x | -5.35 x |
| FCF Yield | - | -14.1% | -24.2% | -12.4% | -20.3% | -14.1% | -23.9% | -18.7% |
| Price to Book | - | 4.46 x | 1.13 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 27,953 | 38,820 | 58,092 | 58,560 | 58,822 | 59,414 | - | - |
| Reference price 2 | 5.810 | 6.860 | 4.000 | 6.960 | 3.510 | 4.160 | 4.160 | 4.160 |
| Announcement Date | 20-03-12 | 21-03-11 | 22-03-17 | 23-03-09 | 24-03-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 33.17 | 24.78 | 57.03 |
| EBITDA 1 | - | - | -55.96 | -62.42 | - | -38.4 | -42.36 | -28.49 |
| EBIT 1 | -63.07 | -36.42 | -56.22 | -62.68 | -42.79 | -26.27 | -43.95 | -31.67 |
| Operating Margin | - | - | - | - | - | -79.21% | -177.37% | -55.53% |
| Earnings before Tax (EBT) 1 | -62.14 | -38.03 | -57.78 | -62.02 | -37.54 | -11.72 | -40.74 | -27.23 |
| Net income 1 | -60.83 | -37.55 | -57.78 | -62.02 | -37.54 | 4.723 | -25.85 | -17.46 |
| Net margin | - | - | - | - | - | 14.24% | -104.34% | -30.62% |
| EPS 2 | -2.240 | -1.110 | -1.070 | -1.060 | -0.6400 | 0.0520 | -0.4260 | -0.2667 |
| Free Cash Flow 1 | - | -37.49 | -56.29 | -50.7 | -41.92 | -34.8 | -59 | -46.2 |
| FCF margin | - | - | - | - | - | -104.92% | -238.12% | -81.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-12 | 21-03-11 | 22-03-17 | 23-03-09 | 24-03-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | 23.5 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -9.333 | -8.827 | -10.47 | -11.66 |
| EBIT 1 | -15.4 | -16.48 | -17.71 | -14.78 | -13.7 | -16.8 | -10.34 | -9.55 | -6.098 | -9.394 | -9.51 | -10.74 | -10.98 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | -46.71% |
| Earnings before Tax (EBT) 1 | -15.75 | -16.79 | -17.78 | -14.55 | -12.9 | -15.62 | -8.987 | -8.187 | -4.753 | -8.082 | -9.57 | -10.33 | -10.98 |
| Net income 1 | -15.75 | -16.79 | -17.78 | -14.55 | -12.9 | -15.62 | -8.987 | -8.187 | -4.753 | -8.082 | -9.57 | -10.33 | -10.96 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -46.65% |
| EPS 2 | -0.2700 | -0.2900 | -0.3000 | -0.2500 | -0.2200 | -0.2700 | -0.1500 | -0.1400 | -0.0800 | -0.1400 | -0.1650 | -0.1825 | 0.2967 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 22-03-17 | 22-05-05 | 22-08-05 | 22-11-10 | 23-03-09 | 23-05-04 | 23-08-03 | 23-11-03 | 24-03-07 | 24-05-02 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | 214 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -37.5 | -56.3 | -50.7 | -41.9 | -34.8 | -59 | -46.2 |
| ROE (net income / shareholders' equity) | - | - | -43.6% | -34.8% | -27.7% | -39% | -27.6% | -13.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | 1.540 | 3.540 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.01 | - | 0.01 | 0.02 | - | - | 2.8 | 3.3 |
| Capex / Sales | - | - | - | - | - | - | 11.3% | 5.79% |
| Announcement Date | 20-03-12 | 21-03-11 | 22-03-17 | 23-03-09 | 24-03-07 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.16
USD
Average target price
9.25
USD
Spread / Average Target
+122.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.52% | 247M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- ALDX Stock
- Financials Aldeyra Therapeutics, Inc.
